BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Dr. Helen M. Thackray FAAP, M.D.

Chief Research & Development Officer

Dr. William P. Sheridan MBBS

Chief Development Officer

Ms. Stephanie  Angelini

Chief People Officer

Mr. Anthony J. Doyle

Senior Vice President, Chief Financial Officer & Treasurer

Mr. Charles K. Gayer

Senior Vice President & Chief Commercial Officer

Mr. Michael L. Jones

Executive Director of Finance & Principal Accounting Officer

Mr. Jon P. Stonehouse

Chief Executive Officer, President & Executive Director

Ms. Alane P. Barnes

Senior Vice President, Chief Legal Officer & Corporate Secretary

Mr. John D. Bluth

Chief Communications Officer

Dr. Yarlagadda S. Babu

Chief Discovery Officer

Биотехнологии

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. Структура на управлението

Информация за управлението